Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) EBT Margin (2016 - 2025)

Myriad Genetics (MYGN) has disclosed EBT Margin for 17 consecutive years, with 4.24% as the latest value for Q4 2025.

  • Quarterly EBT Margin rose 1432.0% to 4.24% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 47.92% through Dec 2025, down 3319.0% year-over-year, with the annual reading at 47.92% for FY2025, 3318.0% down from the prior year.
  • EBT Margin for Q4 2025 was 4.24% at Myriad Genetics, up from 12.74% in the prior quarter.
  • The five-year high for EBT Margin was 23.79% in Q3 2021, with the low at 155.14% in Q2 2025.
  • Average EBT Margin over 5 years is 25.21%, with a median of 17.01% recorded in 2023.
  • The sharpest move saw EBT Margin surged 6076bps in 2021, then tumbled -13755bps in 2025.
  • Over 5 years, EBT Margin stood at 27.05% in 2021, then decreased by -8bps to 29.3% in 2022, then surged by 44bps to 16.43% in 2023, then decreased by -13bps to 18.57% in 2024, then skyrocketed by 77bps to 4.24% in 2025.
  • According to Business Quant data, EBT Margin over the past three periods came in at 4.24%, 12.74%, and 155.14% for Q4 2025, Q3 2025, and Q2 2025 respectively.